From OSN APAO

Ozurdex for retinal vein occlusion available in China

Ozurdex is now available in China for the treatment of adult patients with macular edema secondary to retinal vein occlusion, Allergan announced in a press release.

Ozurdex (dexamethasone intravitreal implant 0.7 mg) was approved in October 2017 and is the first intravitreal injection approved for RVO in China.

“RVO is a devastating condition that affects millions of patients in China. ... Being able to offer these patients a proven treatment option allows ophthalmologists to consider a more tailored management approach, helping to reduce the treatment burden for patients and alleviate pressure on local eye care services,” Dai Hong, director of ophthalmology at Beijing Hospital, said in the release.

Ozurdex is now available in China for the treatment of adult patients with macular edema secondary to retinal vein occlusion, Allergan announced in a press release.

Ozurdex (dexamethasone intravitreal implant 0.7 mg) was approved in October 2017 and is the first intravitreal injection approved for RVO in China.

“RVO is a devastating condition that affects millions of patients in China. ... Being able to offer these patients a proven treatment option allows ophthalmologists to consider a more tailored management approach, helping to reduce the treatment burden for patients and alleviate pressure on local eye care services,” Dai Hong, director of ophthalmology at Beijing Hospital, said in the release.